Uganda's Mandatory Newborn Sickle Cell Disease Screening Programme: Translating a Decade of Evidence into Differentiated Implementation.

IF 1.8 Q2 PEDIATRICS
Pediatric health, medicine and therapeutics Pub Date : 2026-09-03 eCollection Date: 2026-01-01 DOI:10.2147/PHMT.S621156
Bwambale Jonani, Betty Nakawuka, Enock Ssebunya, Richard Kwizera, Felix Bongomin, Gerald Mboowa
{"title":"Uganda's Mandatory Newborn Sickle Cell Disease Screening Programme: Translating a Decade of Evidence into Differentiated Implementation.","authors":"Bwambale Jonani, Betty Nakawuka, Enock Ssebunya, Richard Kwizera, Felix Bongomin, Gerald Mboowa","doi":"10.2147/PHMT.S621156","DOIUrl":null,"url":null,"abstract":"<p><p>Uganda's sickle cell disease (SCD) prevalence of 1.3% and sickle cell trait (SCT) prevalence of 13.3% nationally represent a substantial public health burden, with an estimated 20,000 affected infants born annually. On 9 February 2026, Uganda's Ministry of Health launched a nationwide mandatory newborn screening programme for SCD, placing the country among the first in sub-Saharan Africa to implement universal birth screening. This policy builds on over a decade of evidence, including the Uganda Sickle Surveillance Study, and cost-effectiveness analyses showing dried blood spot (DBS) screening costs of $5.88 per child, with viable point-of-care thresholds of $3.07-$5.09. However, the initial rollout relies on rapid diagnostic tests within existing hub-and-CPHL systems and does not yet fully cover private facility births, immunization-based catch-up for missed cases, or older unscreened children. In addition, the current 4-6-week turnaround time with centralized confirmation at Central Public Health Laboratories remains an operational limitation. We propose a differentiated implementation framework to strengthen the programme. It aligns screening strategies with care entry points and age-specific test performance. Private facilities would use a microchip electrophoresis analyzer (Gazelle™) at birth due to reduced accuracy of lateral flow tests in high fetal hemoglobin. Public facilities would integrate Sickle SCAN or HemoTypeSC into immunization contacts from six weeks of age, with the 9-month contact prioritized as the most reliable screening timepoint given the progressive decline in HbF, and school-based programmes would target children aged 1-5 years who were previously missed. All pathways would connect to Uganda's 100-laboratory hub network for electrophoretic confirmation, potentially reducing turnaround time to 48-72 hours. By leveraging existing delivery, immunization, and laboratory infrastructure, this framework offers a feasible and equitable route to translate Uganda's mandatory screening policy into large-scale health impact.</p>","PeriodicalId":74410,"journal":{"name":"Pediatric health, medicine and therapeutics","volume":"17 ","pages":"621156"},"PeriodicalIF":1.8000,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13549171/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric health, medicine and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/PHMT.S621156","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Uganda's sickle cell disease (SCD) prevalence of 1.3% and sickle cell trait (SCT) prevalence of 13.3% nationally represent a substantial public health burden, with an estimated 20,000 affected infants born annually. On 9 February 2026, Uganda's Ministry of Health launched a nationwide mandatory newborn screening programme for SCD, placing the country among the first in sub-Saharan Africa to implement universal birth screening. This policy builds on over a decade of evidence, including the Uganda Sickle Surveillance Study, and cost-effectiveness analyses showing dried blood spot (DBS) screening costs of $5.88 per child, with viable point-of-care thresholds of $3.07-$5.09. However, the initial rollout relies on rapid diagnostic tests within existing hub-and-CPHL systems and does not yet fully cover private facility births, immunization-based catch-up for missed cases, or older unscreened children. In addition, the current 4-6-week turnaround time with centralized confirmation at Central Public Health Laboratories remains an operational limitation. We propose a differentiated implementation framework to strengthen the programme. It aligns screening strategies with care entry points and age-specific test performance. Private facilities would use a microchip electrophoresis analyzer (Gazelle™) at birth due to reduced accuracy of lateral flow tests in high fetal hemoglobin. Public facilities would integrate Sickle SCAN or HemoTypeSC into immunization contacts from six weeks of age, with the 9-month contact prioritized as the most reliable screening timepoint given the progressive decline in HbF, and school-based programmes would target children aged 1-5 years who were previously missed. All pathways would connect to Uganda's 100-laboratory hub network for electrophoretic confirmation, potentially reducing turnaround time to 48-72 hours. By leveraging existing delivery, immunization, and laboratory infrastructure, this framework offers a feasible and equitable route to translate Uganda's mandatory screening policy into large-scale health impact.

乌干达强制性新生儿镰状细胞病筛查方案:将十年证据转化为差异化实施。
乌干达镰状细胞病(SCD)的流行率为1.3%,镰状细胞特征(SCT)的流行率为13.3%,这是一个巨大的公共卫生负担,估计每年有20,000名受影响的婴儿出生。2026年2月9日,乌干达卫生部启动了一项全国性的SCD强制性新生儿筛查规划,使该国成为撒哈拉以南非洲首批实施普遍出生筛查的国家之一。这项政策建立在十多年来的证据基础上,包括乌干达镰状病监测研究,以及成本效益分析显示,干血斑(DBS)筛查成本为每名儿童5.88美元,可行的医疗点阈值为3.07- 5.09美元。然而,最初的推广依赖于现有的中心和初级卫生保健中心系统内的快速诊断测试,尚未完全覆盖私人设施的分娩、基于免疫的遗漏病例补发或未筛查的年龄较大的儿童。此外,目前在中央公共卫生实验室集中确认的4-6周周转时间仍然是一个操作限制。我们提出一个有区别的执行框架,以加强该方案。它将筛查策略与护理切入点和特定年龄的测试表现结合起来。由于高胎儿血红蛋白侧流测试的准确性降低,私人机构将在婴儿出生时使用微芯片电泳分析仪(Gazelle™)。公共设施将从6周龄开始将镰刀扫描或血型esc纳入免疫接触者,鉴于乙肝病毒的逐渐下降,9个月接触者优先作为最可靠的筛查时间点,以学校为基础的规划将针对以前错过的1-5岁儿童。所有途径都将连接到乌干达的100个实验室中心网络进行电泳确认,可能将周转时间缩短至48-72小时。通过利用现有的交付、免疫和实验室基础设施,该框架提供了一条可行和公平的途径,将乌干达的强制性筛查政策转化为大规模的健康影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书